

53
54
55. A method according to claim 51 wherein the pharmaceutically or cosmetically acceptable excipient is propylene glycol alginate.

56. A method according to claim 51 wherein the pharmaceutically or cosmetically acceptable excipient is hyaluronic acid or salts or derivatives thereof.

57. A method for preparing an active enamel substance for promoting the take of a graft in a mammal, comprising
admixing an active enamel substance and a pharmaceutically or cosmetically acceptable excipient.

rule 58
r. 12.6 59. A method according to claim 57 wherein the pharmaceutically or cosmetically acceptable excipient is propylene glycol alginate.

59
60. A method according to claim 57 wherein the pharmaceutically or cosmetically acceptable excipient is hyaluronic acid or salts or derivatives thereof.

REMARKS

Claims 1-27 have been cancelled without prejudice, and claims 32-60 have been added. No new matter has been added by virtue of the new claims. For instance, support for the new claims appears e.g. on page 16, lines 13-16 and the original claims of the application.

Applicants respectfully request reconsideration of the Restriction Requirement. It is believed that all the pending claims could be searched and examined together without undue burden. It also would save considerable time and expense for both the Office and Applicants to have all pending claims considered at this time. Reconsideration of the Restriction is solicited.

In any event, to provide a complete response, Applicants elect Group II as that Group is defined in the Office Action. That Group includes original claims 28-31 as well as new claims 32-56, which are each dependent from claim 28.


To ensure a complete response, Applicants also repond to the species election:

A) as a type of graft, Applicants elect a cartilage graft;

B) as a type of active enamel substance, Applicants elect enamelines; as a molecular weight, Applicants elect between about 5,000 and 25,000 kDa; and as a type of excipient, Applicants elect propylene glycol alginate.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,



Peter F. Corless, Reg. No. 33,860
EDWARDS & ANGELL, LLP
Dike, Bronstein, Roberts & Cushman IP Group
130 Water Street
Boston, Massachusetts 02109-4280
Tel. (617) 523-3400
Fax (617) 523-6440